SEARCH
Suven Life Sciences misses target for Alzheimers molecule SUVN 502
CNBC-TV18
2019-12-02
Views
460
Description
Share / Embed
Download This Video
Report
Suven Life Sciences has missed their target for SUVN 502 - a molecule which they were banking on for Alzheimers and outlicensing opportunity. Venkat Jasti, chairman and CEO of Suven Life Sciences shared more details and the future course of action.
Show more
Share This Video
facebook
google
twitter
linkedin
email
Video Link
Embed Video
<iframe width="600" height="350" src="https://vntv.net//embed/x7oox15" frameborder="0" allowfullscreen></iframe>
Preview Player
Download
Report form
Reason
Your Email address
Submit
RELATED VIDEOS
03:55
Avion hypersonique, galaxies et Alzheimer, les 8 actus sciences que vous devez connaître ce 6 juillet
00:37
Mimbela hits the target but misses the goal
00:47
Chipotle Misses Q2 Revenue Target, Warns Of Flat 2025 Sales
01:44
ADVANCED RIFLE NEVER MISSES its target. Tracking Point Rifle great for US Military
01:03
US Says Houthi Missile Aimed For American Oil Tanker In Gulf Of Aden Misses Target
00:43
Target Misses Q3 Earnings and Revenue, Cuts Full-Year Profit Guidance Despite Price Cuts on 10,000 Items to Attract More Shoppers
03:05
NHS misses targets despite better performance
06:13
Funny Target Practice Fails 2016 - Hits And Misses by FailArmy
01:20
Google fourth quarter revenue misses Wall Street target
03:29
After many misses, Renault sets ambitious target for Kwid
06:45
BUSINESS DAILY - Hollande misses target of reducing unemployment
00:39
Eli Lilly Misses Q3 Targets, Lowers Full-Year Outlook on Weak Zepbound, Mounjaro Sales